InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
CEO: Moshe Mizrahy. Company website
InMode Ltd. (INMD) trades at $14.35, down 1.31% on the day, as of Sep 20, 2026 14:57 UTC.
InMode Ltd. has a market capitalisation of $824.85M, calculated from the live INMD share price and shares outstanding.
INMD trades at a trailing P/E of 11.67, from earnings per share of $1.23 over the last twelve months.
InMode Ltd. generated revenue of $374.63M over the trailing twelve months, which puts the stock at 2.20 times sales.
INMD has traded between $12.72 and $16.74 over the past 52 weeks, and the last price is 14.3% below that high.
Yes. InMode Ltd. keeps 20.69% of revenue as net income over the trailing twelve months.
Wall Street analysts rate INMD Hold, with an average price target of $19.00, 32.4% above the current price.
InMode Ltd. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in IL.
Moshe Mizrahy is the chief executive of InMode Ltd., which employs 660 people.
QFI Terminal shows INMD with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open INMD in Terminal See plans